The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis

References

• Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–426. doi: 10.1056/NEJMoa0902533.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594–1604. doi: 10.1177/1352458517727603.
   PubMed Web of Science ®Google Scholar
• Leist TP, Comi G, Cree BA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13(3):257–267. doi: 10.1016/S1474-4422(14)70005-5.
   PubMed Web of Science ®Google Scholar
• Freedman MS, Leist TP, Comi G, et al. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study. Mult Scler J Exp Transl Clin. 2017;3(4):2055217317732802. doi: 10.1177/2055217317732802.
   Google Scholar
• Baker D, Pryce G, Herrod SS, et al. Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord. 2019;30:176–186. doi: 10.1016/j.msard.2019.02.018.
   PubMed Web of Science ®Google Scholar
• Comi G, Cook S, Giovannoni G, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168–174. doi: 10.1016/j.msard.2019.01.038.
   PubMed Web of Science ®Google Scholar
• Stuve O, Soelberg Soerensen P, Leist T, et al. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Ther Adv Neurol Disord. 2019;12:1756286419854986. doi: 10.1177/1756286419854986.
   Web of Science ®Google Scholar
• Heinz W, Klaus S, Suzanne H, et al. Specific patterns of immune cell dynamics may explain the early onset and prolonged efficacy of cladribine tablets. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200048.
   PubMed Web of Science ®Google Scholar
• Cook S, Leist T, Comi G, et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019;29:157–167. doi: 10.1016/j.msard.2018.11.021.
   PubMed Web of Science ®Google Scholar
• Leist T, Cook S, Comi G, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020;46:102572. doi: 10.1016/j.msard.2020.102572.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Berger J, Leist T, et al. Post-approval safety of cladribine tablets with particular reference to COVID-19 outcomes: an update (P106). Mult Scler. 2022;28(1S):68–69.
   Google Scholar
• Moccia M, Lanzillo R, Petruzzo M, et al. Single-center 8-years clinical follow-up of cladribine-treated patients from phase 2 and 3 trials. Front Neurol. 2020;11:489. doi: 10.3389/fneur.2020.00489.
   PubMed Web of Science ®Google Scholar
• Disanto G, Moccia M, Sacco R, et al. Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years. Mult Scler Relat Disord. 2022;58:103490. doi: 10.1016/j.msard.2022.103490.
   PubMed Web of Science ®Google Scholar
• Chisari CG, Toscano S, D'Amico E, et al. An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opin Drug Saf. 2019;18(10):925–948. doi: 10.1080/14740338.2019.1658741.
   PubMed Web of Science ®Google Scholar
• Butzkueven H, Kappos L, Wiendl H, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the tysabri observational program (TOP). J Neurol Neurosurg Psychiatry. 2020;91(6):660–668. doi: 10.1136/jnnp-2019-322326.
   PubMed Web of Science ®Google Scholar
• Dirks P, Zingler V, Leemhuis J, et al. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in german real world multiple sclerosis cohorts - the CONFIDENCE study protocol. BMC Neurol. 2020;20(1):95. doi: 10.1186/s12883-020-01667-7.
   PubMed Web of Science ®Google Scholar
• Butzkueven H, Moore N, Aydemir A, et al. The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets. Curr Med Res Opin. 2022;38(7):1167–1176. doi: 10.1080/03007995.2022.2059977.
   PubMed Web of Science ®Google Scholar
• Watson SP. Poisson regression models for interval censored count data. Baylor University, Waco, Texas; 2011.
   Google Scholar
• Collett D. Modelling binary data. New York, USA: Chapman & Hall/CRC; 2003.
   Google Scholar
• Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985; 4(2):213–226. doi: 10.1002/sim.4780040211.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Kern R, Voigt I, et al. Data collection in multiple sclerosis: the MSDS approach. Front Neurol. 2020;11:445. doi: 10.3389/fneur.2020.00445.
   PubMedGoogle Scholar
• Rauma I, Viitala M, Kuusisto H, et al. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Mult Scler Relat Disord. 2022;61:103755. doi: 10.1016/j.msard.2022.103755.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Pontieri L, Joensen H, et al. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: a danish nationwide study. Mult Scler Relat Disord. 2023;70:104491. doi: 10.1016/j.msard.2022.104491.
   PubMed Web of Science ®Google Scholar
• Spelman T, Ozakbas S, Alroughani R, et al. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry. Mult Scler. 2023;29(2):221–235. doi: 10.1177/13524585221137502.
   PubMed Web of Science ®Google Scholar
• Fischer S, Proschmann U, Akgün K, et al. Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects. Cells. 2021;10(11):3177. doi: 10.3390/cells10113177.
   PubMed Web of Science ®Google Scholar
• Kingwell E, Marriott JJ, Jette N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013;13(1):128. doi: 10.1186/1471-2377-13-128.
   PubMedGoogle Scholar
• He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307–316. doi: 10.1016/S1474-4422(20)30067-3.
   PubMed Web of Science ®Google Scholar
• Torgauten HM, Myhr KM, Wergeland S, et al. Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis: a cohort study. Mult Scler J Exp Transl Clin. 2021;7(1):2055217320973049. doi: 10.1177/2055217320973049.
   Google Scholar
• Hänninen K, Viitala M, Atula S, et al. Initial treatment strategy and clinical outcomes in finnish MS patients: a propensity-matched study. J Neurol. 2022;269(2):913–922. doi: 10.1007/s00415-021-10673-9.
   PubMed Web of Science ®Google Scholar